AUGUST 2013 VOLUME 36 SUPPLEMENT 2

Diabetes Care

Introduction

5111 Introduction to the 4th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy) S. Del Prato, I. Raz

I. Diabetes Pathophysiology

5113 Role of reduced β -cell mass versus impaired β -cell function in the pathogenesis of type 2 diabetes *J.J. Meier, R.C. Bonadonna*

\$120 Genetic screening for the risk of type 2 diabetes: worthless or valuable?

V. Lyssenko, M. Laakso

\$127 Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes

R.A. DeFronzo, R. Eldor, M. Abdul-Ghani

5139 Guideline approach to therapy in patients with newly diagnosed type 2 diabetes *I. Raz*

\$145 GLP-1 effects on islets: hormonal, neuronal, or paracrine? *M.Y. Donath, R. Burcelin*

II. Diabetes Therapy

5149 Is physical exercise a core therapeutical element for most patients with type 2 diabetes? *P. De Feo, P. Schwarz*

5155 Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013 *G. Schernthaner, C.J. Currie, G.-H. Schernthaner*

5162 In vivo actions of peroxisome proliferator–activated receptors: glycemic control, insulin sensitivity, and insulin secretion

R. Eldor, R.A. DeFronzo, M. Abdul-Ghani

\$175 Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes

C.F. Burant

5180 How do we continue treatment in patients with type 2 diabetes when therapeutic goals are not reached with oral antidiabetes agents and lifestyle? Incretin versus insulin treatment

B. Gallwitz, R.G. Bretzel

III. Insulin Therapy

\$190 Early insulinization to prevent diabetes progression *I. Raz, O. Mosenzon*

\$198 Insulin as an early treatment for type 2 diabetes: ORIGIN or end of an old question?

S. Del Prato, C. Bianchi, A. Dardano, R. Miccoli

5205 Is there evidence to support use of premixed or prandial insulin regimens in insulin-naive or previously insulin-treated type 2 diabetic patients?

H. Yki-Järvinen, A. Kotronen

5212 Intensification of insulin therapy for type 2 diabetic patients in primary care: basal-bolus regimen versus premix insulin analogs: when and for whom?

O. Mosenzon, I. Raz

\$219 Insulin pump for type 2 diabetes: use and misuse of continuous subcutaneous insulin infusion in type 2 diabetes *Y. Reznik, O. Cohen*

\$226 Combining incretin-based therapies with insulin: realizing the potential in type 2 diabetes *J. Vora*

IV. Diabetes and Cancer

5233 Epidemiology and molecular mechanisms tying obesity, diabetes, and the metabolic syndrome with cancer *E.J. Gallagher, D. LeRoith*

\$240 Insulin therapy and cancer *P. Home*

5245 Do GLP-1-based therapies increase cancer risk? *M.A. Nauck, N. Friedrich*

V. The Heart in Diabetes

\$253 Cardiovascular outcome studies with novel antidiabetes agents: scientific and operational considerations *B. Hirshberg, A. Katz*

\$259 Is glucose control important for prevention of cardiovascular disease in diabetes?

E. Mannucci, I. Dicembrini, A. Lauria, P. Pozzilli

5264 The case for: hypoglycemia is of cardiovascular importance *N.M. Lalic*

5267 Cardiovascular importance of hyperglycemia and hypoglycemia I. *Tkáč*

\$272 Glycemic variability: both sides of the story A. Ceriello, E.S. Kilpatrick

VI. Obesity

\$276 Obesity paradox does exist *V. Hainer, I. Aldhoon-Hainerová*

5282 Defending the con side: obesity paradox does not exist *E. Standl, M. Erbach, O. Schnell*

5287 Mechanism of metabolic advantages after bariatric surgery: it's all gastrointestinal factors versus it's all food restriction *F.K. Knop, R. Taylor*

5292 Targets for body fat, blood pressure, lipids, and glucose-lowering interventions in healthy older people *C. Tsigos, R. Bitzur, Y. Kleinman, H. Cohen, A. Cahn, G. Brambilla, G. Mancia, G. Grassi*

VII. Hypertension

5301 Individualization of antihypertensive drug treatment G. Mancia, G. Grassi

\$307 Ambulatory blood pressure monitoring in the diagnosis and management of hypertension *E. Grossman*

\$312 Prognostic value of blood pressure variability and average blood pressure levels in patients with hypertension and diabetes *G. Parati, J.E. Ochoa, P. Salvi, C. Lombardi, G. Bilo*

5325 Intolerance to statins: mechanisms and management R. Bitzur, H. Cohen, Y. Kamari, D. Harats